Posts

Posted on

Gabelli Dividend & Income Trust Continues Monthly Distributions, Declaring Distributions of $0.11 Per Share

Gabelli Dividend & Income Trust Continues Monthly Distributions, Declaring Distributions of $0.11 Per Share

RYE, N.Y.–(BUSINESS WIRE)–
The Board of Trustees of The Gabelli Dividend & Income Trust (NYSE:GDV) (the “Fund”) approved the continuation of its policy of paying fixed monthly cash distributions. The Board of Trustees declared cash distributions of $0.11 per share for each of January, February, and March 2021.

Distribution Month

Record Date

Payable Date

January

January 14, 2021

January 22, 2021

February

February 11, 2021

February 19, 2021

March

March 17, 2021

March 24, 2021

Additionally, the Board of Trustees continues to evaluate potential strategic opportunities for the Fund in what we believe to be an attractive environment to invest in the broader equity markets.

Each quarter, the Board of Trustees reviews the amount of any potential distribution from the income, realized capital gain, or capital available. The Board of Trustees will continue to monitor the Fund’s distribution level, taking into consideration the Fund’s net asset value and the financial market environment. If necessary, the Fund will pay an adjusting distribution in December which includes any additional income and net realized capital gains in excess of the monthly distributions for that year to satisfy the minimum distribution requirements of the Internal Revenue Code for regulated investment companies. The Fund’s distribution policy is subject to modification by the Board of Trustees at any time, and there can be no guarantee that the policy will continue. The distribution rate should not be considered the dividend yield or total return on an investment in the Fund.

All or part of the distribution may be treated as long-term capital gain or qualified dividend income (or a combination of both) for individuals, each subject to the maximum federal income tax rate for long term capital gains, which is currently 20% in taxable accounts for individuals (or less depending on an individual’s tax bracket). In addition, certain U.S. shareholders who are individuals, estates or trusts and whose income exceeds certain thresholds will be required to pay a 3.8% Medicare surcharge on their “net investment income”, which includes dividends received from the Fund and capital gains from the sale or other disposition of shares of the Fund.

If the Fund does not generate sufficient earnings (dividends and interest income, less expenses, and realized net capital gain) equal to or in excess of the aggregate distributions paid by the Fund in a given year, then the amount distributed in excess of the Fund’s earnings would be deemed a return of capital. Since this would be considered a return of a portion of a shareholder’s original investment, it is generally not taxable and would be treated as a reduction in the shareholder’s cost basis.

Long-term capital gains, qualified dividend income, investment company taxable income, and return of capital, if any, will be allocated on a pro-rata basis to all distributions to common shareholders for the year. Based on the accounting records of the Fund currently available, each of the distributions paid to common shareholders in 2020 would include approximately 16% from net investment income and 84% from net capital gains on a book basis. This does not represent information for tax reporting purposes. The estimated components of each distribution are updated and provided to shareholders of record in a notice accompanying the distribution and are available on our website (www.gabelli.com). The final determination of the sources of all distributions in 2020 will be made after year end and can vary from the monthly estimates. Shareholders should not draw any conclusions about the Fund’s investment performance from the amount of the current distribution. All individual shareholders with taxable accounts will receive written notification regarding the components and tax treatment for all 2020 distributions in early 2021 via Form 1099-DIV.

Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing. More information regarding the Fund’s distribution policy and other information about the Fund is available by calling 800-GABELLI (800-422-3554) or visiting www.gabelli.com.

About The Gabelli Dividend & Income Trust

The Gabelli Dividend & Income Trust is a diversified, closed-end management investment company with $2.4 billion in total net assets whose primary investment objective is to provide a high level of total return with an emphasis on dividends and income. The Fund is managed by Gabelli Funds, LLC, a subsidiary of GAMCO Investors, Inc. (NYSE:GBL).

NYSE – GDV

CUSIP – 36242H104

Investor Relations Contact:

Carter Austin

(914) 921-5475

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Posted on

Arrowhead Interim Clinical Data Demonstrate ARO-AAT Treatment Improved Multiple Biomarkers of Alpha-1 Liver Disease

Arrowhead Interim Clinical Data Demonstrate ARO-AAT Treatment Improved Multiple Biomarkers of Alpha-1 Liver Disease

– Serum Z-AAT reductions of 86-93%

– All patients demonstrated greater than 80% reduction in liver Z-AAT monomer

– 3 of 4 patients had a decrease in liver globule involvement

– 3 of 4 patients demonstrated reductions in Z-AAT polymer with a range of 68-97%

– All patients showed ALT reductions ranging from 36-66%

PASADENA, Calif.–(BUSINESS WIRE)–
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced positive interim clinical data from AROAAT2002, an open-label Phase 2 clinical study of ARO-AAT, the company’s second-generation investigational RNA interference (RNAi) therapeutic being developed as a treatment for the rare genetic liver disease associated with alpha-1 antitrypsin deficiency (AATD). The data demonstrate that three doses of ARO-AAT over 24-weeks resulted in consistent reductions of the disease-causing mutant Z protein (Z-AAT) and improvements in clinically relevant biomarkers of liver disease. The results were presented in a late-breaking poster at The Liver Meeting Digital Experience, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD).

A copy of the poster may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

Javier San Martin, M.D., chief medical officer at Arrowhead, said: “These data presented at AASLD strongly suggest that ARO-AAT is doing what it’s designed to do, which is reduce the production of the misfolded mutant Z-AAT protein. Moreover, these compelling results indicate that the liver may have the ability to clear out accumulated Z-AAT and begin to heal itself faster than anticipated. Importantly, we saw reductions in serum Z-AAT and liver Z-AAT which led to improvements in multiple markers, such as liver globules, ALT/GGT and Pro-C3. These are all positive indications of a strong pharmacodynamic response and improvement in liver health, following just three doses of ARO-AAT. We anticipate data from additional patient cohorts will be available in the coming months, which will be included in our planned discussions with the U.S. Food and Drug Administration and other regulatory agencies, aimed at exploring areas where the ARO-AAT program could potentially be streamlined and accelerated.”

In the AROAAT2002 study, four patients with homozygous PiZZ alpha-1 antitrypsin deficiency and evidence of fibrosis at screening, each received three doses of ARO-AAT on week 0, 4, and 16. Liver biopsies were performed at screening and at week 24. Assessments included safety (including pulmonary function tests), changes in serum Z-AAT, liver Z-AAT, ALT, GGT, Pro-C3, liver elastography (FibroScan®), and liver globule assessment. Additional histologic adjudication is ongoing.

Key data presented include the following:

Pharmacodynamic Response at 24 weeks

  • Serum Z-AAT reductions were 86-93%
  • Total intra-hepatic Z-AAT reductions were 72-95%
  • All patients demonstrated greater than 80% reduction in liver Z-AAT monomer (soluble)
  • 3 of 4 patients demonstrated reductions in Z-AAT polymer (insoluble) with a range of 68-97%
  • 3 of 4 patients had a decrease in liver globule involvement and 1 subject remained unchanged
  • All patients showed reductions in ALT (range 36-66%) and in GGT (range 43-58%)
  • 3 of 4 patients demonstrated a substantial reduction of greater than 20% in FibroScan® values
  • 3 of 4 patients showed greater than 30% reduction in serum Pro-C3, a marker of fibrogenesis

Safety

  • Overall, ARO-AAT 200 mg as a subcutaneous injection was well tolerated in PiZZ AATD subjects
  • One treatment emergent SAE of Epstein bar virus related myocarditis was reported
  • No treatment emergent AEs related to change in pulmonary status or pulmonary function were reported
  • No clinically meaningful changes in ppFEV1 from baseline to Week 24 were observed

In October 2020, Arrowhead and Takeda Pharmaceutical Company Limited announced a collaboration and licensing agreement to develop ARO-AAT. Under the terms of the agreement, Arrowhead and Takeda will co-develop ARO-AAT which, if approved, will be co-commercialized in the U.S. under a 50/50 profit-sharing structure. Outside the U.S., Takeda will lead the global commercialization strategy and receive an exclusive license to commercialize ARO-AAT with Arrowhead eligible to receive tiered royalties of 20-25% on net sales. Arrowhead will receive an upfront payment of $300 million and is eligible to receive potential development, regulatory and commercial milestones up to $740 million. Closing of the transaction is contingent on completion of review under antitrust laws, including the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the U.S.

AROAAT2002 (NCT03946449) is a pilot open-label, multi-dose, Phase 2 study to assess the response to ARO-AAT in approximately 16 patients with AATD associated liver disease and baseline liver fibrosis who will be enrolled in three cohorts. All eligible participants will require a pre-dose biopsy and an end of study biopsy. Treated participants will also be offered the opportunity to continue treatment in an open-label extension (OLE). Including the OLE, interim assessments will be made after 6 months and 18 months (cohorts 1, 1b), and 12 months and 24 months (cohort 2) of treatment with ARO-AAT. Arrowhead is also evaluating ARO-AAT in the ongoing SEQUOIA Phase 2/3 trial, which began in August 2019.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company’s email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Source: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.

Vince Anzalone, CFA

626-304-3400

[email protected]

Investors:

LifeSci Advisors, LLC

Brian Ritchie

212-915-2578

[email protected]

www.lifesciadvisors.com

Media:

LifeSci Communications, LLC

Josephine Belluardo, Ph.D.

646-751-4361

[email protected]

www.lifescicommunications.com

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Pharmaceutical Genetics Health Clinical Trials

MEDIA:

Logo
Logo
Posted on

OLB Group, Announces Third Quarter Results

OLB Group, Announces Third Quarter Results

NEW YORK–(BUSINESS WIRE)–
The OLB Group, Inc. (NASDAQ: OLB) (“OLB” or the “Company”), a FinTech company, has announced financial results for third quarter ended September 30, 2020 and is providing an update on other company developments.

OLB is a FinTech company and a payment facilitator that, through its subsidiaries, focuses on a suite of products in the merchant services and payment facilitator verticals. These services include electronic payment processing, cloud-based multi-channel commerce platform solutions for small to medium sized businesses and crowd funding services. The Company is focused on providing these integrated business solutions to merchants throughout the United States through three wholly-owned subsidiaries, eVance, Inc., Omnisoft.io, Inc., and CrowdPay.us, Inc.

Financial Highlights

  • Revenues for the nine months ended September 30, 2020 were $6,922,065.
  • Adjusted EBITDA for the nine months ended September 30, 2020 was $157,748.

Highlights of financial results for the nine months ended September 30, 2020 (unaudited) are as follows:

 

For the Nine

Months Ended

September 30, 2020

Total revenue

$

6,922,065

Total operating expenses

$

7,768,546

Loss from operations

$

(846,481)

Total other expense

$

(863,493)

Net Loss

$

(1,709,974)

 

 

 

Amortization and depreciation expense

$

616,813

Interest expense

$

865,397

EBITDA

$

(227,764)

Stock Based Compensation expenses

$

385,512

Adjusted EBITDA

$

157,748

 

As a result of the response to the COVID-19 pandemic in the United States, OLB did experience disruptions to its business as a result of disruptions with its customers and merchants, which resulted in a decline in transaction volume during April, May and June. Since June and through September 30, the Company had an overall increase in the number of transactions compared to the monthly transactions processed in March through May.

Key Highlights During Third Quarter of 2020 and Subsequent Events

  • OLB closed a successful capital raise with Aegis Capital receiving gross proceeds of $6.4 million.
  • Completed uplisting of OLB common stock to NASDAQ Capital Markets trading under the symbol OLB
  • Reduced debt by approximately $6.1 to approximately $7.6 million by converting $4.6 million of debt into equity and paying down $1.5 million of the Company’s senior debt (we had $13.9 million of indebtedness the same time last year).
  • Increased ecommerce business merchants during third quarter compared to retail (brick and mortar) merchants
  • Ronny Yakov, Chief Executive Officer, appeared on The RedChip Money Report television program.
  • OLB Group Expands Support for Apple Pay, Google Pay and ACH
  • OLB Group Simplifies SMB Billing Through QuickBooks Connection
  • National Sports Services Selects OLB to provide cloud-based cashless and contactless omnicommerce solutions for Four Minor League Baseball Teams
  • Integration of a comprehensive 3D Secure service for OLB’s merchants through its proprietary Secure Pay payment gateway

To see a complete version of the Company’s Quarterly Report on Form 10-Q please click on the following link:

https://www.sec.gov/Archives/edgar/data/1314196/000121390020036572/f10q0920_theolbgroup.htm

About The OLB Group, Inc. (OLB)

The OLB Group, Inc. is a payment facilitator and commerce service provider that delivers fully outsourced private label shopping solutions to highly trafficked websites and retail locations. The Company provides end-to-end e-commerce, mobile and retail solutions to customers. These services include electronic payment processing, cloud-based multi-channel commerce platform solutions for small to medium-sized businesses and crowdfunding services. The Company is focused on providing these integrated business solutions to merchants throughout the United States through three wholly-owned subsidiaries, eVance, Inc., Omnisoft.io, Inc., and CrowdPay.us, Inc.

OLB Group, Inc.’s common stock is traded on the NASDAQ Capital Market under the stock symbol: OLB. Additional information about the Company can be found at http://www.olb.com

About Non-GAAP Financial Measures

This press release contains non-GAAP financial measures, Net Loss before Interest, Taxes, Depreciation and Amortization (“EBITDA”) and adjusted EBITDA, as defined in Regulation G. The Company reports its financial results in compliance with GAAP, but also provides additional non-GAAP measures of its operating results. The Company defines EBITDA as net loss, before interest, taxes, depreciation and amortization. The Company defines adjusted EBITDA as EBITDA, as defined above, adding back non-cash stock option costs and certain non-recurring items, such as costs incurred with completing acquisitions. These measures may not be comparable to similarly titled measures reported by other companies. Management believes the use of EBITDA and adjusted EBITDA is appropriate to enhance the understanding by the Company’s investors of its historical performance through use of a metric that seeks to normalize earnings.

Forward Looking Statements

All statements from The OLB Group, Inc. in this news release that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, but are not limited to, statements concerning the impact of COVID-19 on our operations and financial condition our ability to implement our proprietary merchant boarding and CRM system and to roll out our Omni Commerce applications to our current merchants and the integration of our secure payment gateway with our crowd funding platform. While the Company’s management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not limited to, uncertainty regarding our ability to integrate the companies that we have recently acquired and to repay outstanding indebtedness and fund our operations. For other factors that may cause our actual results to differ from those that are expected, see the information under the caption “Risk Factors” in the Company’s most recent Form 10-K and Form 10-Q filings, and amendments thereto, as well as other public filings with the SEC since such date. The Company operates in a rapidly changing and competitive environment, and new risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. The Company disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statement.

To get news updates about the company please register https://olb.com/category/news/

Investors & Analysts Contact:

Investor Relations

(212) 278-0900 EXT 333

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Software Finance Banking Data Management Small Business Professional Services Technology Security

MEDIA:

Logo
Logo
Posted on

SINTX Technologies and Iwatani Group Announce Agreement to Develop Antipathogenic Surfaces to Help Prevent Spread of the Common Flu, COVID-19, and Other Viral Diseases

SINTX Technologies and Iwatani Group Announce Agreement to Develop Antipathogenic Surfaces to Help Prevent Spread of the Common Flu, COVID-19, and Other Viral Diseases

SALT LAKE CITY–(BUSINESS WIRE)–
SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”) (www.sintx.com), an original equipment manufacturer (OEM) of silicon nitride ceramic for medical and non-medical applications, and Iwatani Corporation of America (ICA), a wholly-owned subsidiary of Iwatani Corporation, announced today that they have entered into a joint development agreement.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201113005116/en/

Photo of an example of proposed applications. (Photo: Business Wire)

Photo of an example of proposed applications. (Photo: Business Wire)

The goal of this agreement is to incorporate SINTX AP2 silicon nitride powder into polymer materials. These materials will become safe and effective surfaces for IT devices such as cases for cell phones and tablets that are touched frequently. SINTX and Iwatani aim to create surfaces that resist bacteria and viruses. The successful development of these products may help prevent and reduce the spread of respiratory diseases like SARS-CoV-2, Influenza A, and H1N1 by inactivating viruses and bacteria on the polymer surfaces.

“We are pleased to enter this joint development agreement with Iwatani, toward developing new products that leverage the intrinsic antipathogenic properties of silicon nitride,” said Dr. Bal. “The collaboration with Iwatani is intended to directly apply our material science expertise toward new product development and revenues, a very significant and exciting move for SINTX.”

SINTX and Iwatani intend to capitalize on recent and promising data demonstrating the potential of SINTX AP2silicon nitride powder to inactivate the SARS-CoV-2 virus that is responsible for the global COVID-19 pandemic. Studies showing the rapid inactivation of SARS-CoV-2 by SINTX’s silicon nitride are the latest in a series of papers showing similar activity of silicon nitride against a variety of bacteria and viral strains. SINTX and Iwatani plan to jointly fund collaborative product development activities in Salt Lake City, Utah, and Japan with the support of external laboratories as well.

SINTX notes they are working diligently to incorporate silicon nitride into several products such as masks and consumer electronic products and other surfaces that will help inactivate respiratory pathogens. The joint development agreement between Iwatani and SINTX will help SINTX advance their materials science, while external partners like Iwatani develop commercial products that can help protect the worldwide community against viral diseases.

About SINTX Technologies, Inc.

SINTX Technologies is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications. The core strength of SINTX Technologies is the manufacturing, research, and development of silicon nitride ceramics for external partners. The Company presently manufactures silicon nitride powders and components in its FDA registered, AS9100D certified, and ISO 13485:2016 certified manufacturing facility.

For more information on SINTX Technologies or its silicon nitride material platform, please visit www.sintx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) that are subject to a number of risks and uncertainties. Risks and uncertainties that may cause such differences include, among other things, SINTX’s ability to complete its obligations under the agreement; the collaboration with Iwatani may not result in the development of any products; that SINTX has not as yet developed any products with antiviral properties which incorporate the use of silicon nitride; products developed under the joint development agreement may not be effective against the SARS-CoV-2 virus; incorporation of silicon nitride into personal protective equipment may not be safe or effective; volatility in the price of SINTX’s common stock; the uncertainties inherent in new product development, including the cost and time required to commercialize such product(s); market acceptance of our products once commercialized; SINTX’s ability to raise additional funding and other competitive developments. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 26, 2020, and in SINTX’s other filings with the SEC. SINTX disclaims any obligation to update any forward-looking statements. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.

Business Inquiries for SINTX:

SINTX Technologies

801.839.3502

[email protected]

Media Inquiries for SINTX:

Amanda Barry

Associate Director, Content and PR

The Summit Group

[email protected]

KEYWORDS: Utah United States North America

INDUSTRY KEYWORDS: Technology FDA Packaging Engineering Chemicals/Plastics Health Manufacturing Consumer Other Technology Research Infectious Diseases Other Consumer Science Textiles

MEDIA:

Photo
Photo
Photo of an example of proposed applications. (Photo: Business Wire)
Posted on

Domo Webinar to Feature Expert Analyst on Growing Trend of Data Commercialization

Domo Webinar to Feature Expert Analyst on Growing Trend of Data Commercialization

Discussion to Focus on Taking Data to Market and Driving New Revenue Models

SILICON SLOPES, Utah–(BUSINESS WIRE)–Domo (Nasdaq: DOMO), provider of the Domo Business Cloud, today announced it will be hosting a webinar featuring Forrester Principal Analyst Jennifer Belissent, PhD, and Domo’s Chris Haleua to discuss how organizations can leverage data commercialization opportunities to unlock more value from their business data.

The webinar will take place on Monday, November 16, at 11:00 a.m. MT. To register for the “Explore Data Commercialization Opportunities: A Guide to Taking Your Data to Market” webinar, visit here.

Digital transformation initiatives have created a wealth of valuable data. A typical use of this business data focuses on data monetization, either as cost savings from operational insights or as revenue growth from customer insights. The next step of data usage, data commercialization, takes that business data to market, and extends its use to business partners or customers in the form of a data-derived product or value-added service. In fact, 54% of companies commercialize their data in some form, up from 32% in 2016.*

Join Domo’s webinar featuring Forrester to:

  • Learn about best practices in data commercialization across industries;
  • Explore potential use cases for data/insights products and services;
  • Understand relevant product design methodologies, pricing strategies, partnership models, and organizational structures; and,
  • Discuss the implications for taking data to market, and how to socialize the opportunity with potential stakeholders.

To learn more about how Domo has helped more than 1,800 industry-leading, innovative and disruptive companies drive more value from their business data inside and outside their organizations, visit Domo’s customer page.

About Domo

Domo is the Business Cloud, empowering organizations of all sizes with BI leverage at cloud scale, in record time. With Domo, BI-critical processes that took weeks, months or more can now be done on-the-fly, in minutes or seconds, at unbelievable scale. For more information about how Domo (Nasdaq: DOMO) helps its customers go fast, go big and go bold, visit www.domo.com. You can also follow Domo on Twitter, Facebook and LinkedIn.

Domo, Domo Business Cloud and Domo is the Business Cloud are registered trademarks of Domo, Inc.

*According to Forrester Analytics “Business Technographics Data And Analytics Survey, 2016 & 2020”

Cynthia Cowen

[email protected]

KEYWORDS: United States North America Utah

INDUSTRY KEYWORDS: Professional Services Data Management Technology Software Consulting Internet

MEDIA:

Logo
Logo
Posted on

Aerie Makes Sharing Kindness Simple This Holiday Season, Just Dial 1.844.KIND.365

Aerie Makes Sharing Kindness Simple This Holiday Season, Just Dial 1.844.KIND.365

Leading Intimates Brand Launches #AerieREAL Kind Campaign to Share a Special Kind of Kind this Holiday Season…AerieREAL Kind

NEW YORK–(BUSINESS WIRE)–
American Eagle Outfitters, Inc. (NYSE:AEO) today announces Aerie’s latest initiative in support of its ongoing mission to empower its community — and sharing kindness is at the center of it all. In honor of World Kindness Day, the brand launches its #AerieREAL Kind Campaign inclusive of its first-ever #AerieREAL Kind Hotline, surprise #AerieREAL Acts of Kindness, a partnership with Feeding America®, and a new Holiday ‘20 collection that feels REAL good.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201113005100/en/

Aerie Holiday '20 Campaign (Photo: Business Wire)

Aerie Holiday ’20 Campaign (Photo: Business Wire)

“Aerie is a community built on helping all people love their real selves and we recognize that we have the ability to share even more kindness with our community during a season when we could all appreciate a little extra love,” said Jennifer Foyle, Chief Creative Officer, AEO Inc. & Global Brand President, Aerie. “The elements of the #AerieREAL Kind Campaign are meant to spark learning, sharing, action and giving back. It is our hope that by opening up the lens and dialogue on what it means to be kind, we will inspire our community to choose kindness today, and always.”

LEARN & SHARE

Aerie is kicking off its campaign with the debut of the #AerieREAL Kind Hotline, a place for its community to “visit” whenever, and wherever, to receive a message about a special kind of kind — the #AerieREAL Kind. Today, through December 25th, callers who dial 1.844.KIND.365 will be invited to choose their kindness journey with prompts leading them to customized voice messages, in both English and Spanish, by Aerie friends including Storm Reid, Melissa Wood Health, Katherine Schwarzenegger, and Jillian Mercado; #AerieREAL Role Models Aly Raisman, Iskra, Manuela Baron, Keiana Cave, Tiff McFierce, Dre Thomas; and more. The “Kindness Advocates” will encourage callers to share kindness through personal stories and tips ranging from how to be kind to yourself and to others, as well as how to share kindness online and with the world.

ACT

Spurring the hotline kindness into action, Aerie will also give its community the opportunity to pay it forward. As part of the campaign, customers will be invited to nominate a deserving person in their lives for an #AerieREAL Act of Kindness. The process is simple; by heading over to #AerieREAL Life, customers can submit their nominee for a random surprise and delight moment. The acts will be personalized to the nominee’s unique story ranging from support with paying a bill, to treating a friend to dinner, to having the chance to speak to one of the “Kindness Advocates” LIVE; a few will even be curated by the “Kindness Advocates” and #AerieREAL Role Models. Submissions will be valid today through November 20th with the acts of kindness taking place throughout the month of December.

GIVE BACK

As part of the campaign’s mission, Aerie has partnered with Feeding America® to help those who are facing hunger. In celebration of the campaign launch, the brand will donate five meals* for every purchase, up to 500,000 meals, this weekend (November 13th-November 15th). For every purchase made on the brand’s REAL Rewards credit card, Aerie will donate 20 meals, up to one million meals, through November 25th. On Giving Tuesday, Aerie will donate ten meals for every REAL Rewards transaction, up to 100,000 meals.

IT FEELS GOOD TO GIVE AERIE

Aerie’s new Holiday ‘20 collection was designed to remind its community that despite spending more time at home, home is the place where we feel the most REAL. New for the season, the brand introduces matching lounge sets, waffle henleys, sherpa outerwear, “Good Vibes” fleece tops and joggers, and eclectic sweaters, along with leggings, bike shorts, sports bras and more from its new sub-brand OFFLINE by Aerie. While sharing kindness doesn’t always include a gift, it does feel REAL good to give Aerie and the brand’s collection offers a new assortment of the perfect giftable accessories.

* $1 helps to provide at least ten meals secured by Feeding America® on behalf of local member food banks.

About Aerie

Aerie is a lifestyle brand offering intimates, apparel, activewear and swim collections. With the #AerieREAL™ movement, Aerie celebrates its community by advocating for body positivity and the empowerment of all women. Aerie believes in inspiring customers to love their real selves, inside and out. Retouching-free since 2014. Visit www.aerie.com to learn more. Let the Real You Shine®.

About American Eagle Outfitters, Inc.

American Eagle Outfitters, Inc. (NYSE: AEO) is a leading global specialty retailer offering high-quality, on-trend clothing, accessories and personal care products at affordable prices under its American Eagle® and Aerie® brands. Our purpose is to show the world that there’s REAL power in the optimism of youth. The company operates stores in the United States, Canada, Mexico, and Hong Kong, and ships to 81 countries worldwide through its websites. American Eagle and Aerie merchandise also is available at more than 200 international locations operated by licensees in 25 countries. For more information, please visit www.aeo-inc.com.

Matthew Owens

SHADOW

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Fashion Retail Consumer Other Retail Department Stores Hispanic

MEDIA:

Photo
Photo
Aerie Holiday ’20 Campaign (Photo: Business Wire)
Logo
Logo
Posted on

Wolters Kluwer Lien Solutions Offers U.S. Lenders Risk Mitigation Strategies Amid COVID-19 Challenges to Foster Growth in ABA Banking Journal

Wolters Kluwer Lien Solutions Offers U.S. Lenders Risk Mitigation Strategies Amid COVID-19 Challenges to Foster Growth in ABA Banking Journal

HOUSTON–(BUSINESS WIRE)–
With COVID-19 cases continuing to surge in the United States and small business defaults rising sharply, U.S. commercial lenders can mitigate their risks through a range of loan portfolio risk management strategies to weather economic headwinds and promote long-term growth. That’s according to Wolters Kluwer Lien Solutions in a new thought leadership article published in the American Bankers Association’s (ABA) Banking Journal.

While economic stimulus programs have been enacted, funding from some of those efforts is beginning to dry out, leaving small businesses in a precarious situation. But in spite of significant volatility in today’s commercial lending space, there are ways for lenders to mitigate the risks, notes Raja Sengupta, Executive Vice President and General Manager, Lien Solutions, in this feature article, “Navigating a New Era in Commercial Lending.”

“A thorough review of loan documents is necessary to determine to what extent borrowers may be, or are likely to become, in default of financial covenants or in breach of representations and warranties or other covenants, or are required to provide notice to their lenders of their current or anticipated circumstances,” writes Sengupta. “Further emphasis should be placed upon secured loans, to ensure that liens are perfected and that the collateral can be secured.”

Sengupta notes that for cash-strapped businesses facing a potentially prolonged period of reduced demand, bankruptcy “may be an attractive route to managing their debt burden. Lenders thus face a delicate balancing act between leniency and stringency for borrowers in distress.”

He writes that strong rigor around workouts can benefit both borrower and lender as a valuable way to mitigate a wave of defaults. But not all circumstances necessitate a workout, and the practice should be employed only when necessary, such as when the borrower’s prospects in the future look bright and they are receptive to negotiations.

“Lenders can build stronger relationships during volatile times by offering resources for borrowers to take advantage of, such as networking or federal loan assistance, Sengupta notes. “There are many ways to keep borrowers afloat until they recover. It’s well worth their time to explore all of the available options.”

First published in 1908, the ABA Banking Journal—the American Bankers Association’s flagship magazine—provides insights that help banking leaders succeed in the competitive financial services market. It is read by more than 20,000 bank leaders nationwide.

Lien Solutions, which is part of Wolters Kluwer’s Governance, Risk & Compliance (GRC) division, provides award-winning solutions for lenders. Its flagship iLien offering gives lenders the ability to conduct public record searches, retrieve and view Uniform Commercial Code (UCC) and corporate records, create filings, and manage their entire lending portfolio. iLien Manageis a suite of award-winning, web-based solutions that enable lenders to manage and address risks in their entire UCC lien portfolio with analytics, visibility and automation. Its iLien Motor Vehicleoffering is an award-winning SaaS platform that transforms vehicle and equipment titling work, helping lenders maintain loan perfection, monitor and manage vehicle liens efficiently, and release titles effortlessly.

Wolters Kluwer’s GRC division provides an array of expert solutions to help U.S. financial institutions manage regulatory and risk obligations, including customized offerings to address COVID-19 challenges. Lien Solutions’ iLien for Main Street helps lenders optimize their due diligence and lien management efforts when securing loans for small and medium-sized businesses under the Main Street Lending Program. In addition, Wolters Kluwer Compliance Solutions’ Paycheck Protection Program Supported by TSoftPlus™ helps lenders’ customers access critical stimulus funding.

About Wolters Kluwer Governance, Risk & Compliance

Governance, Risk & Compliance is a division of Wolters Kluwer, which provides legal and banking professionals with solutions to help ensure compliance with ever-changing regulatory and legal obligations, manage risk, increase efficiency, and produce better business outcomes. GRC offers a portfolio of technology-enabled expert services and solutions focused on legal entity compliance, legal operations management, banking product compliance, and banking regulatory compliance.

Wolters Kluwer (AEX: WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors. Wolters Kluwer reported 2019 annual revenues of €4.6 billion. The company, headquartered in Alphen aan den Rijn, the Netherlands, serves customers in over 180 countries, maintains operations in over 40 countries and employs 19,000 people worldwide.

Paul Lyon

Director of Global Corporate Communications, Banking & Regulatory Compliance

Governance, Risk & Compliance

Wolters Kluwer

Office +44 20 3197 6586

[email protected]

David Feider

Corporate Communications Manager, Banking & Regulatory Compliance

Governance, Risk & Compliance Division

Wolters Kluwer

Tel: +1 612-852-7966

[email protected]

On Twitter: @davidafeider

KEYWORDS: Europe United States Netherlands North America Texas

INDUSTRY KEYWORDS: Consulting Banking Accounting Technology Professional Services Small Business Other Technology Software Other Professional Services Legal Finance

MEDIA:

Logo
Logo
Posted on

New Voya Financial Post-Election Study Finds Almost Eight in 10 Americans Feel “Kindness” Is Most Important Personal Value

New Voya Financial Post-Election Study Finds Almost Eight in 10 Americans Feel “Kindness” Is Most Important Personal Value

An array of mixed sentiment felt by Americans after the election gives way to clear consensus on the need to come together — now more than ever.

The vast majority of those polled (93%) believe spreading “kindness” needs to be a fundamental tenet for companies, especially those in the financial services sector.

NEW YORK–(BUSINESS WIRE)–
Voya Financial, Inc. (NYSE: VOYA) announced today, on World Kindness Day, results of a new, post-election study* that found the majority of Americans feel kindness is the most important personal value an individual should exhibit — with almost eight in 10 of those polled (78%) ranking kindness as the highest in a list of personal values.

Rounding out the top five values ranked by those polled are:

  • Fairness (71%)
  • Justice (67%)
  • Ethics (63%)
  • Diversity (47%)

The Voya study also found that, in addition to being kind, 96% of those polled would like to see more kindness in the future. And nearly all Americans (97%) agree acts of kindness can help make the world a better place.

“I could not think of a better message to share on World Kindness Day than to join the vast majority of Americans in emphasizing just how important it is to be kind to one another,” said Rodney O. Martin, Jr., chairman and CEO, Voya Financial. “Being kind every day is not just the right thing to do for each other — being kind fosters a shared, community spirit of respect and inclusion that can lift up society.”

Mixed feelings now — but unity moving forward

Voya’s research shows Americans have varied feelings in the wake of the 2020 election. Specifically, those polled say they are:

  • Optimistic (48%)
  • Uncertain (36%)
  • Worried (28%)
  • Disappointed (23%)
  • Energized (22%)

Overwhelmingly, though, Voya found that — regardless of how people may be feeling right now — Americans feel the need to come together. More than nine in 10 (94%) of those polled expressed this sentiment.

A world of kindness … in the workplace and beyond

Among the study’s key findings is how important people feel about “kindness” as a core operating principle for companies. Specifically, 93% of those polled said they want to work for a company that supports spreading kindness. That same level of importance is stressed in financial services, as 93% of respondents felt companies in the industry should take a stand on treating all Americans with respect and kindness.

In addition, 80% of those polled said corporate philanthropy is one way that a company can demonstrate its commitment to acts of kindness. Further, nine in 10 Americans (90%) said it is important for companies to encourage employee kindness through charitable gift matching, paid volunteering opportunities and other programs.

“Voya and its employees share a commitment to the communities in which we live and work — and to enhancing the lives of people around the world,” said Martin, referring to ways in which the company is promoting a brighter, kinder future. Those efforts include the Voya Cares® program; Voya’s kindness campaign, in collaboration with 9-year-old Lily Allison and singer-songwriter Mandy Harvey; the impact of Voya’s employee volunteerism and charitable giving; and employee donation gift matching from Voya Foundation.

Voya encourages its employees to contribute to their communities. The company provides full-time employees with 40 hours of paid volunteer time each year and Voya Foundation — the company’s charitable giving arm — matches employee charitable giving up to $5,000 per employee for eligible nonprofits.

For additional information on Voya’s corporate responsibility efforts, please read the company’s 2019-2020 Impact Report.

*Based on the results of a Voya Financial survey conducted through AYTM – Ask Your Target Market online research platform between Nov. 9-10, 2020 among n=1,000 Americans age 18+, balanced by age, gender, and region to reflect the U.S. population.

About Voya Financial®

Voya Financial, Inc. (NYSE: VOYA), helps Americans plan, invest and protect their savings — to get ready to retire better. Serving the financial needs of approximately 13.8 million individual and institutional customers in the United States, Voya is a Fortune 500 company that had $7.5 billion in revenue in 2019. The company had $657 billion in total assets under management and administration as of Sept. 30, 2020. With a clear mission to make a secure financial future possible — one person, one family, one institution at a time — Voya’s vision is to be America’s Retirement Company®. Certified as a “Great Place to Work” by the Great Place to Work® Institute, Voya is equally committed to conducting business in a way that is socially, environmentally, economically and ethically responsible. Voya has been recognized as a 2020 World’s Most Admired Company by Fortune magazine; one of the 2020 World’s Most Ethical Companies® by the Ethisphere Institute; as a member of the Bloomberg Gender Equality Index; and as a “Best Place to Work for Disability Inclusion” on the Disability Equality Index by Disability:IN. For more information, visit voya.com. Follow Voya Financial on Facebook, LinkedIn and Twitter @Voya.

About Voya Cares®

An extension of Voya’s vision and mission to help all Americans have the quality of life they seek in retirement, the Voya Cares program is committed to being a leader in making a positive difference in the lives of individuals with special needs and disabilities — as well as their families, caregivers and other providers — by offering a depth of resources focused on education, planning and solutions. Go to voyacares.com to learn more.

VOYA-IR VOYA-CR

Jessica Speziale

Voya Financial

Phone: (646) 284-3063

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo
Logo
Posted on

Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences

BURNABY, British Columbia, Nov. 13, 2020 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon’s Chief Executive Officer, will participate in the following virtual investor conferences:

  • Guggenheim Healthcare 2nd Annual Neuro/Immunology Day on Monday, November 16, 2020
  • Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17, 2020 at 4:40 pm ET
  • Jefferies Virtual London Healthcare Conference on Thursday, November 19, 2020 at 9:40 am ET (2:40 pm GMT)

The above listed dates and times are subject to change. Details on company presentations and webcasts can be found on the “Investors” section of Xenon’s website at www.xenon-pharma.com. When available, webcasts will be posted for replay following the event for 30 days.


About Xenon Pharmaceuticals Inc.

We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: [email protected]



Posted on

Bank of Commerce Holdings Announces Santa Rosa, CA Loan Production Office

SACRAMENTO, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) — Bank of Commerce Holdings (NASDAQ: BOCH) (the “Company”), a $1.740 billion asset bank holding company and parent company of Merchants Bank of Commerce (the “Bank”), today announced the Bank’s expansion to San Francisco’s North Bay markets through the opening of a Loan Production Office (LPO) in Santa Rosa on December 1, 2020. The LPO will be led by Steve Tagnolli whose title will be Senior Vice President, North Bay Regional Manager. The Bank fully intends to transition the LPO into a full service deposit and loan operation.

“This expansion of our operations into the North Bay aligns with our strategic vision of pursuing opportunities in economically attractive markets near our existing footprint and led by talented bankers,” said Randy Eslick, President and Chief Executive Officer. “I am pleased and excited to have Steve join our team. He is a highly skilled and experienced banker, and a lifelong resident of the North Bay who is well known in these attractive markets.”

 “I am thrilled to be a part of a company that can pivot during an unprecedented global pandemic and expand their services into the North Bay. As a 3rd generation Santa Rosan, I look forward to building a talented team to provide the exceptional service Merchants Bank of Commerce is known for,” said Steve Tagnolli, Regional Manager.

About Bank of Commerce Holdings

Bank of Commerce Holdings is a bank holding company headquartered in Sacramento, California and is the parent company for Merchants Bank of Commerce. The Bank is an FDIC-insured California banking corporation providing community banking and financial services in northern California’s wine country and the Sacramento Valley along the Interstate 5 corridor from Sacramento to Yreka. The Bank was incorporated as a California banking corporation on November 25, 1981 and opened for business on October 22, 1982. The Company’s common stock is listed on the NASDAQ Global Market and trades under the symbol “BOCH”.

Contact Information

Randall S. Eslick, President and Chief Executive Officer
Telephone Direct (916) 677-5800

James A. Sundquist, Executive Vice President and Chief Financial Officer
Telephone Direct (916) 677-5825

Andrea M. Newburn, Vice President and Senior Administrative Officer / Corporate Secretary
Telephone Direct (530) 722-3959